CHRONIC MIGRAINE RESULTS
≥15 to ≤26 headache days per month, of which ≥8 were migraine days.1 One month was defined as 28 consecutive days.2
4 to 14 headache days per month, of which ≥4 were migraine days.1†
Over 20% of patients experienced at least 75% fewer migraine days during Months 1-3 (22.2% vs 16.2% with placebo, not significant)1†
Early benefit seen within the first 7 days, and as soon as Day 1 post-infusion1‡
Reduced mean monthly migraine days by ~50% through Month 6 (vs 28-42% with placebo)1,4§¶
*Data from VYEPTI 100 mg dose groups.1
†One month was defined as 28 consecutive days.4
‡Data represent mean percent of patients based on observed data.1
§This is a prespecified endpoint but not prespecified analyses.4
¶Calculated from the percent change from baseline; percentages for VYEPTI range from 43-55%.4
≥15 to ≤26 headache days per month, of which ≥8 were migraine days.1†
~27% of patients on VYEPTI experienced at least 75% fewer migraine days during Months 1-3 (26.7% vs 15% with placebo, p<0.001)1†
Early benefit seen within the first 7 days, and as soon as Day 1 post-infusion1‡
Reduced mean monthly migraine days by ~50% through Month 6 (vs 30-39% with placebo)1,4§¶
*Data from VYEPTI 100 mg dose groups.1
†One month was defined as 28 consecutive days.2
‡Data represent mean percent of patients based on observed data.1
§This is a prespecified endpoint but not prespecified analyses.1
¶Calculated from the percent change from baseline; percentages for VYEPTI range from 47-54%.4
PROMISE-2 was a parallel-group, double-blind, placebo-controlled global trial to evaluate the efficacy and safety of VYEPTI for the preventive treatment of chronic migraine in adults. A total of 1072 patients were randomized and received placebo (n=366), VYEPTI 100 mg (n=356), or VYEPTI 300 mg (n=350) every 3 months for 6 months.2
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.
VYEPTI is indicated for the preventive treatment of migraine in adults.
Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Full Prescribing Information and Patient Information.
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.
VYEPTI is indicated for the preventive treatment of migraine in adults.
Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Full Prescribing Information and Patient Information.